Skip to main content
Log in

A dose response study with bacampicillin in uncomplicated gonorrhoea

Dosis-Wirkung-Studie mit Bacampicillin bei unkomplizierter Gonorrhöe

  • Clinical Evaluation
  • Published:
Infection Aims and scope Submit manuscript

Summary

In a systematic study of dose-response relationship 883 patients with uncomplicated gonorrhoea were given single oral doses of 400, 800 or 1600 mg bacampicillin, with 1 g probenecid. A single dose of bacampicillin 800 mg plus probenecid was the minimum effective dose in patients with fully ampicillin-sensitive strains. In patients with gonococci showing reduced sensitivity to ampicillin, 1600 mg bacampicillin was required to reach a cure rate above 95%. Bacampicillin was well tolerated in all treatment groups. Side-effects were reported in 4.6% of the courses of treatment. The most frequent adverse reaction was loose stools (1.9%), which was noted more often after the 1600 mg dose but was considered to be of no or very little clinical importance.

Zusammenfassung

In einer systematischen Studie über die Dosis-Wirk-Beziehung wurden an 883 Patienten mit unkomplizierter Gonorrhöe Einzeldosen von 400, 800 und 1600 mg Bacampicillin mit 1 g Probenecid verabreicht. Eine Einzeldosis von 800 mg Bacampicillin plus Probenecid war das Minimum für eine wirksame Behandlung bei Patienten mit voll Ampicillin empfindlichen Stämmen. Bei Patienten mit Gonokokken, die vermindert Ampicillin empfindlich waren, wurden 1600 mg Bacampicillin benötigt, um eine Heilungsrate von 95% zu erzielen. Bacampicillin wurde in allen Behandlungsgruppen gut vertragen. Von Nebenwirkungen wurde bei 4,6% aller Behandlungszyklen berichtet. Die häufigste Reaktion waren weiche Stühle (1,9%), die häufiger nach der 1600 mg Dosis beobachtet wurden, denen jedoch keine oder nur geringe klinische Bedeutung beigemessen wurde.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Literature

  1. Bodin, N.-O., Ekström, B., Forsgren, K., Jalar, L.-P., Magni, L., Ramsay, C.-H., Sjöberg, B. Bacampicillin: A new orally well-absorbed derivative of ampicillin. Antimicrob. Agents Chemother. 8 (1975) 518–525.

    Google Scholar 

  2. Magni, L., Sjöberg, B., Sjövall, J., Wessman, J. Clinical pharmacological studies with bacampicillin. In:Williams, J. O., Geddes, A. M. (ed).: Chemotherapy, Vol. 5: Penicillins and Cephalosporins, Plenum Press, New York, 1976, 109–114.

    Google Scholar 

  3. Sjövall, J., Magni, L., Bergan, T. Pharmacokinetics of bacampicillin compared to ampicillin, pivampicillin, and amoxycillin. Antimicrob. Agents Chemother. 13 (1978) 90–96.

    Google Scholar 

  4. Eriksson, G. Oral ampicillin in uncomplicated gonorrhoea IV. Comparison of pharmacological and clinical results. Acta Derm. Venereol. (Stockholm) 51 (1971) 467–475.

    Google Scholar 

  5. Gästrin, B., Kallings, L.-O. Improved methods for gonococcal sampling and examination on a large scale. Acta Pathol. Microb. Scand. 74 (1968) 362–370.

    Google Scholar 

  6. Gilliet, F., Storck, A. Neues zur Therapie der Gonorrhöe. Schweiz. med. Wschr. 103 (1973) 564–572.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wallin, J., Bengtsson, S., Eriksson, G. et al. A dose response study with bacampicillin in uncomplicated gonorrhoea. Infection 7 (Suppl 5), S487–S488 (1979). https://doi.org/10.1007/BF01659779

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01659779

Keywords

Navigation